Literature DB >> 24941981

Elotuzumab for the treatment of multiple myeloma.

Philippe Moreau1, Cyrille Touzeau.   

Abstract

New agents are awaited for the treatment of multiple myeloma and research is ongoing for the development of monoclonal antibodies (MoAbs) targeting the tumor cells. One of the most promising MoAb is elotuzumab, the only humanized IgG1 MoAb specifically targeting CS1 (SLAMF7), a cell surface glycoprotein that is highly expressed in plasma cells. Preclinical and clinical data on elotuzumab will be presented in this article.

Entities:  

Keywords:  CS1; elotuzumab; lenalidomide; monoclonal antibody; multiple myeloma

Mesh：

Substances：

Year:  2014        PMID： 24941981     DOI： 10.2217/fon.14.56

Source DB:  PubMed          Journal:  Future Oncol        ISSN： 1479-6694            Impact factor:   3.404


  3 in total

1.  SAR650984 directly induces multiple myeloma cell death via lysosomal-associated and apoptotic pathways, which is further enhanced by pomalidomide.

Authors:  H Jiang; C Acharya; G An; M Zhong; X Feng; L Wang; N Dasilva; Z Song; G Yang; F Adrian; L Qiu; P Richardson; N C Munshi; Y-T Tai; K C Anderson
Journal:  Leukemia       Date:  2015-09-04       Impact factor: 11.528

Review 2.  Targeted Therapies in Adult B-Cell Malignancies.

Authors:  Jean-François Rossi
Journal:  Biomed Res Int       Date:  2015-09-06       Impact factor: 3.411

Review 3.  Monoclonal Antibody Therapies for Hematological Malignancies: Not Just Lineage-Specific Targets.

Authors:  Carlos Cuesta-Mateos; Ana Alcaraz-Serna; Beatriz Somovilla-Crespo; Cecilia Muñoz-Calleja
Journal:  Front Immunol       Date:  2018-01-17       Impact factor: 7.561
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.